Table 2. Clinical trials on advanced esophageal cancer in which pembrolizumab was involved.
| Study | Phase | N | Treatment | OS (m, mo) | PFS (m, mo) | ORR (%) | DOR (m, mo) | AEs (≥3, %) |
|---|---|---|---|---|---|---|---|---|
| KEYNOTE-028 | I | 23 | Pembrolizumab | 7 | 1.8 | 30 | 15 | 17.4 |
| KEYNOTE-180 | II | 121 | Pembrolizumab | 5.8 | 2 | 9.9 | Nr | 12.4 |
| KEYNOTE-181 | III | 628 | T1: chemotherapy; T2: pembrolizumab | T1: 7.1; T2: 7.1 | T1: 2.1; T2: 3.4 | T1: 6.7; T2: 13.1 | NR | T1: 40.9; T2: 18 |
| KEYNOTE-590 | III | 749 | T1: chemotherapy + placebo; T2: chemotherapy + pembrolizumab | T1: 9.8; T2: 12.4; HR =0.73, P<0.0001 | T1: 5.8; T2: 6.3; HR =0.65, P<0.0001 |
T1: 29.3; T2: 45.0; | NR | T1: 68; T2: 72 |
N, number; OS, overall survival; PFS, progression-free survival; ORR, overall response rate; DOR, duration of response; m, median; mo, month; %, percent; Nr, not reached; NR, not reported; AEs, adverse reactions.